Early is Good Announces Collaboration with Mayo Clinic to Develop a Comprehensive Liquid Biopsy Test for Men with Advanced Prostate Cancer
Early is Good (EIG), a diagnostic company pioneering multi-omic technology, is pleased to announce a collaboration with Mayo Clinic to develop a comprehensive liquid biopsy for men with advanced prostate cancer.
- Early is Good (EIG), a diagnostic company pioneering multi-omic technology, is pleased to announce a collaboration with Mayo Clinic to develop a comprehensive liquid biopsy for men with advanced prostate cancer.
- This collaboration to develop a comprehensive multi-omic test aims to significantly improve patient outcomes for men with advanced prostate cancer," says Thakshila Liyanage, Ph.D., Founder & CEO of Early is Good.
- This novel liquid biopsy test seeks to enable comprehensive care plans for men with mCRPC.
- Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.